Maze Therapeutics MAZE 深 滬
等待開盤 09-24 09:30:00 美东时间
28.09
-0.290
-1.02%
華盛通- 最 高29.91
- 今 開28.30
- 成交量 170.42万股
- 最 低 27.53
- 昨 收 28.38
- 總市值 15.60亿
- 52周最高 53.65
- 市盈率 靜 --
- 換手率 3.07%
- 52周最低 21.95
- 委 比 50.00%
- 總股本 5554.92万
- 歷史最高 53.65
- 量 比 1.35
- 振 幅 8.39%
- 歷史最低 6.71
- 每 手 1
- 風險率 8.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.
09-23 00:02
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 1% on Monday. Shares of On Holding AG (NYSE:ONON) rose sharply after the company affirmed its FY26 sales guidance above estimates and issued third-quarter sales guidance above estimates. On Holding also announced a $1 billion stock buyb...
09-22 22:25
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
SCYNEXIS appoints Todd Minga, M.D., as Senior Vice President, Research & Development. Dr. Minga brings over 20 years of experience in kidney disease and rare disorders, previously serving as Vice President, Medical Affairs and Clinical Development at Akebia Therapeutics. His expertise will support SCYNEXIS in advancing its rare disease programs, including SCY-770 for ADPKD and SCY-247. Dr. Minga expressed excitement about contributing to the Comp...
09-15 12:00
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics announced its participation in three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026; the Citi 2026 Biopharma Back to School Summit on September 10, 2026; and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live webcasts will be available on the company's website, www.mazetx.com, and archived for 60 days. Maze Therapeutics is a clinical-sta...
09-02 11:00
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.
08-12 18:00
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from the same period last year.
08-12 04:36
Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.56) by 19.64 percent. This is a 60.87 percent increase over losses of $(1.15) per share from
05-13 04:34
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
